Congress Materials - World Conference on Lung Cancer (WCLC 2024)
2024 World Conference on Lung Cancer | Sep 7-10 | San Diego, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study
Shirish M. Gadgeel, Byoung Chul Cho, Shun Lu, Enriqueta Felip, Hidetoshi Hayashi, Alexander I. Spira, Benjamin Besse, Michael Thomas, Scott Owen, Yu Jung Kim, Se-Hoon Lee, Josiane Mourao Dias, Yun-Gyoo Lee, Yanqiu Zhao, Yong Fang, Nicolas Girard, Zhe Liu, Ping Sun, Sulene Cunha Souza Oliveira, Hong Shen, Luis Paz-Ares, Shingo Matsumoto, Hiroshi Tanaka, Azura Rozila Ahmad, Timur Andabekov, Patrapim Sunpaweravong, Ozgur Ozyilkan, James Chih-Hsin Yang, Maya Gottfried, Osvaldo Hernandez, Martin Kimmich, Diego Cortinovis, Diego Lucas Kaen, Lizbett Vanessa García Montes, Sanjay Popat, Thomas Newsom-Davis, John Xie, Tao Sun, Elizabeth Fennema, Mahesh Daksh, Mariah Ennis, Seema Sethi, Joshua M. Bauml, Danny Nguyen
Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-Relevant Outcomes From MARIPOSA
Danny Nguyen, Benjamin Besse, Byoung Chul Cho, Se-Hoon Lee, Ki Hyeong Lee, Shun Lu, Ying Cheng, Yu Yao, Nicolas Girard, Chien-Chung Lin, Enriqueta Felip, Andres Aguilar, Chaiyut Charoentum, Felipe José Silva Melo Cruz, Margarita Majem, Chun Sen Lim, Hiroaki Akamatsu, Hidetoshi Hayashi, James Chih-Hsin Yang, Ruben Kowalyszyn, Katsuki Tiscoski, Fabio Franke, Dmitry Ponomarenko, Cagatay Arslan, Martin Forster, Damien Urban, Daniel Misch, Angelo Delmonte, Lizbett Vanessa García Montes, Shirish M. Gadgeel, Marcia Cruz-Correa, Julio Peguero, Steven Rousey, Yousuf Gaffar, Scott Owen, Julia Schuchard, Joris Diels, Jan Sermon, Tao Sun, Mariah Ennis, Elizabeth Fennema, Mahesh Daksh, Seema Sethi, Joshua M. Bauml, Maria del Rosario Garcia Campelo
Amivantamab, an EGFR-MET Bispecific Antibody, With Cetrelimab, an Anti-PD-1 Antibody, in Advanced NSCLC: Phase 1/2 PolyDamas
Pei Jye Voon, Jiunn-Liang Tan, Alexander I. Spira, Bhumsuk Keam, Se-Hoon Lee, Bing Xia, Eunice Artis, Jessica Dobbs, Christine Baudelet, Mahadi Baig, Joshua M. Bauml, Mehmet Ali Nahit Sendur, Byoung Chul Cho
Development of a Patient-Friendly Lung Cancer Lexicon
Jill Feldman, Nathalie Daaboul, Hatim Husain, Deb Montague, Tejas Patil, Michelle Hull
Enhanced vs Standard Dermatologic Management With Amivantamab-Lazertinib in Advanced NSCLC: Phase 2 COCOON Study
Byoung Chul Cho, Nicolas Girard, Maxwell B. Sauder, Jill Feldman, Weimin Li, Farastuk Bozorgmehr, Milena Mak, Janellen Smith, Jairo Simoes, Parthiv Mahadevia, Bailey G. Anderson, Tonatiuh Romero, Karen Xia, George Wang, Sean P. Murphy, Joshua M. Bauml, Alexander I. Spira
Lazertinib vs Osimertinib in 1L EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA
Se-Hoon Lee, Byoung Chul Cho, Hidetoshi Hayashi, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Yu Jung Kim, Yuriy Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Ki Hyeong Lee, Hailin Xiong, Soon Hin How, Ying Cheng, Gee-Chen Chang, James Chih-Hsin Yang, Benjamin Besse, Michael Thomas, Joshua C Curtin, Jiarui Zhang, John Xie, Tao Sun, Melissa Martinez, Seema Sethi, Roland E Knoblauch, Elizabeth Fennema, Mahesh Daksh, Mariah Ennis, Joshua M. Bauml, Shun Lu
Overall Survival After Treatment With First-line Osimertinib for EGFR-Mutant Advanced NSCLC in the US
Joshua K. Sabari, Helena A. Yu, Parthiv Mahadevia, Yanfang Liu, Levon Demirdjian, Alyshah Abdul Sultan, Yen Hua Chen, Xiayi Wang, Antonio Passaro
PAPILLON: TP53 Co-Mutations, Sites of Insertion, and ctDNA Clearance Among Patients With EGFR Ex20ins-Mutated Advanced NSCLC
Jonathan Goldman, Byoung Chul Cho, Susanna Cheng, Caicun Zhou, Baogang Liu, Yu Yao, Adlinda Alip, Yu Jung Kim, Hector Jose Soto Parra, Tetsuji Kawamura, Osamu Hataji, Hidetoshi Hayashi, Bogdan Zurawski, Ulhas Batra, Victor Santos, Encarnacao Teixeira, Christophe Dooms, Jorge Alatorre-Alexander, Nicolas Girard, Alexander Spira, Chul Kim, Joshua K. Sabari, Sanjay Popat, Keunchil Park, Rachel E. Sanborn, Joshua C. Curtin, Jiarui Zhang, Xuerui Luo, Xuesong Lyu, Archan Bhattacharya, Patricia Lorenzini, Honeylet Wortman-Vayn, Mahadi Baig, Trishala Agrawal, Roland E. Knoblauch, Aaron S. Mansfield
Preventing Infusion-Related Reactions With Intravenous Amivantamab: Primary Results From SKIPPirr, a Phase 2 Study
Gilberto Lopes, Alexander I. Spira, Ji-Youn Han, Jin-Yuan Shih, Céline Mascaux, Upal Basu Roy, Jon Zugazagoitia, Yu Jung Kim, Chao-Hua Chiu, Sang-We Kim, Ernest Nadal, Ignacio Gil-Bazo, Sean P. Murphy, Parthiv Mahadevia, Bailey G. Anderson, Karen Xia, George Wang, Joshua M. Bauml,Marc Chioda, Jairo Simoes, Luis Paz-Ares
Subcutaneous Vs Intravenous Amivantamab: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study
Mariam Alexander, Ying Cheng, Se-Hoon Lee, Antonio Passaro, Alexander I. Spira, Byoung Chul Cho,Sun Min Lim, Yuichiro Ohe, Adnan Nagrial, Jiunn Liang Tan, Vanina Wainsztein, Elisa Ramos, Maria del Rosario Garcia Campelo, Hiroaki Akamatsu, Danny Nguyen, Alexis B. Cortot, Alona Zer, Dilek Erdem, Rachel E. Sanborn, Till-Oliver Emde, Anna R. Minchom, Bogdan Zurawski, Maria Lurdes Ferreira, James Chih-Hsin Yang, Melina E. Marmarelis, Julia Schuchard, Jefferson Alves, Debopriya Ghosh, Remy B. Verheijen, Mohamed Gamil, Joshua M. Bauml, Mahadi Baig, Natasha B. Leighl
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.